Hepatitis D Virus
People with HBV, HIV coinfection at risk for hepatitis D ‘superinfection’
Patients with HIV and hepatitis B coinfection are at an increased risk for hepatitis D, which is associated with an increased risk of liver-related complications and mortality, researchers found.
‘Only one in six’ veterans with chronic HBV finish HDV testing despite severe disease risk
Among veterans with chronic hepatitis B virus infection, rates of hepatitis D virus testing were low and those with concurrent infection were at greater risk for cirrhosis and hepatic decompensation, according to study results.
Anti-HDV positive individuals at ‘significantly higher risk’ for cirrhosis, HCC
Patients who tested positive for hepatitis D virus antibodies were at greater risk for developing hepatocellular carcinoma and other adverse liver-related outcomes, often at a young age, according to study results.
To identify, manage HDV, ‘the simple approach is to just screen’ all patients with HBV
Over recent years, there has been increased interest and attention to hepatitis delta virus, as we are beginning to understand that this is a real problem that at the moment is under-addressed and under-identified.
‘Uncommon’ but not ‘unimportant’: Screen all patients with hepatitis B for HDV
Despite being the smallest virus capable of causing human disease, it is estimated that up to 80% of patients with hepatitis delta virus will progress to liver cirrhosis and more than 50% will die of liver disease within 10 years of diagnosis.
Bulevirtide monotherapy ‘may prevent decompensation but not HCC’ in HDV, cirrhosis
Over 2 years, bulevirtide monotherapy reduced the risk for decompensation and mortality, but not hepatocellular carcinoma, among patients with hepatitis D virus and compensated cirrhosis compared with untreated patients.
Bulevirtide induces a virologic, biochemical response in chronic hepatitis D
Bulevirtide was safe and increased the proportion of patients with undetectable hepatitis D virus RNA among those in both the 2 mg and 10 mg dosage groups, according to data published in The New England Journal of Medicine.
Lonafarnib regimens ‘exceed end-of-treatment response’; oral therapy may be viable in HDV
Treatment with lonafarnib boosted with ritonavir, with or without peginterferon alfa, resulted in significant virological and biochemical response in patients with chronic hepatitis D virus infection, according to data presented.
Behavioral data ‘has the potential’ to predict HCC in patients with hepatitis B
Scoring systems based on behavioral and clinical data outperformed existing scores in predicting risk for hepatocellular carcinoma in patients with chronic hepatitis B virus infection, according to data presented at the EASL Congress.
D-LIVR topline results: Lonafarnib all-oral, combination regimens boost response in HDV
Topline findings from the phase 3 D-LIVR trial showed that lonafarnib — boosted with ritonavir and in combination with peginterferon alfa — improved responses in patients with chronic hepatitis D virus, Eiger BioPharmaceuticals announced.